{"DataElement":{"publicId":"6704127","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome AJCC Edition 8 Tumor T Category","preferredDefinition":"Extent of the primary mycosis fungoides and sezary syndrome tumor using AJCC Ed. 8 criteria.","longName":"MFSS_AJC8_T_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6702712","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome T Category","preferredDefinition":"Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome. --2003_One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","longName":"6702710v1.0:2442923v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6702710","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome","preferredDefinition":"Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome. --2003","longName":"C9265","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome","conceptCode":"C9265","definition":"Mature T and NK neoplasms predominantly affecting the skin and the peripheral blood.  Peripheral blood involvement by abnormal T-cells (cerebriform cells) is a late manifestation of mycosis fungoides, whereas it is the presenting finding in Sezary syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"86CE9C6C-F805-26F5-E053-F662850A0B07","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2442923","version":"1","preferredName":"T Stage","preferredDefinition":"One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","longName":"C25728","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"09046428-57CF-6C1D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-01-10","modifiedBy":"ONEDATA","dateModified":"2006-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"86CE9C6C-F813-26F5-E053-F662850A0B07","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeDescription":"4-18-19 created for standardization; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6703315","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome American Joint Committee on Cancer Edition 8 T Category","preferredDefinition":"A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor (skin)._A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion)._A grouping of items based on some commonality or by user defined characteristics.","longName":"6703315v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"T4","valueDescription":"Mycosis Fungoides and Sezary Syndrome T4 TNM Finding v8","ValueMeaning":{"publicId":"6703317","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome T4 TNM Finding v8","longName":"6703317","preferredDefinition":"Confluence of erythema covering 80% or more of body surface area. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome T4 TNM Finding v8","conceptCode":"C141338","definition":"Confluence of erythema covering 80% or more of body surface area. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D505F8-B7F3-47BB-E053-F662850AA3BF","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86D505F8-B80C-47BB-E053-F662850AA3BF","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","deletedIndicator":"No"},{"value":"T3","valueDescription":"Mycosis Fungoides and Sezary Syndrome T3 TNM Finding v8","ValueMeaning":{"publicId":"6703319","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome T3 TNM Finding v8","longName":"6703319","preferredDefinition":"One or more tumors (equal or greater than 1 cm in diameter). Note: for skin, tumor indicates at least 1 cm diameter solid or nodular lesion with evidence of depth and/or vertical growth. Note the total number of lesions, total volume of lesions, largest size lesion, and region of body involved. Also note whether there is histologic evidence of large-cell transformation. Phenotyping for CD30 is encouraged. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome T3 TNM Finding v8","conceptCode":"C141337","definition":"One or more tumors (equal or greater than 1 cm in diameter). Note: for skin, tumor indicates at least 1 cm diameter solid or nodular lesion with evidence of depth and/or vertical growth. Note the total number of lesions, total volume of lesions, largest size lesion, and region of body involved. Also note whether there is histologic evidence of large-cell transformation. Phenotyping for CD30 is encouraged. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D505F8-B819-47BB-E053-F662850AA3BF","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86D505F8-B832-47BB-E053-F662850AA3BF","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","deletedIndicator":"No"},{"value":"T2b","valueDescription":"Mycosis Fungoides and Sezary Syndrome T2b TNM Finding v8","ValueMeaning":{"publicId":"6703321","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome T2b TNM Finding v8","longName":"6703321","preferredDefinition":"T2b (plaque +/- patch). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome T2b TNM Finding v8","conceptCode":"C141336","definition":"T2b (plaque +/- patch). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D505F8-B83F-47BB-E053-F662850AA3BF","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86D505F8-B858-47BB-E053-F662850AA3BF","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","deletedIndicator":"No"},{"value":"T2a","valueDescription":"Mycosis Fungoides and Sezary Syndrome T2a TNM Finding v8","ValueMeaning":{"publicId":"6703323","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome T2a TNM Finding v8","longName":"6703323","preferredDefinition":"T2a (patch only). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome T2a TNM Finding v8","conceptCode":"C141335","definition":"T2a (patch only). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D505F8-B865-47BB-E053-F662850AA3BF","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86D505F8-B87E-47BB-E053-F662850AA3BF","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","deletedIndicator":"No"},{"value":"T2","valueDescription":"Mycosis Fungoides and Sezary Syndrome T2 TNM Finding v8","ValueMeaning":{"publicId":"6703325","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome T2 TNM Finding v8","longName":"6703325","preferredDefinition":"Patches, papules, or plaques covering 10% or more of the skin surface.  (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome T2 TNM Finding v8","conceptCode":"C141334","definition":"Patches, papules, or plaques covering 10% or more of the skin surface.  (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D505F8-B88B-47BB-E053-F662850AA3BF","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86D505F8-B8A4-47BB-E053-F662850AA3BF","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","deletedIndicator":"No"},{"value":"T1b","valueDescription":"Mycosis Fungoides and Sezary Syndrome T1b TNM Finding v8","ValueMeaning":{"publicId":"6703327","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome T1b TNM Finding v8","longName":"6703327","preferredDefinition":"T1b (plaque +/- patch). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome T1b TNM Finding v8","conceptCode":"C141333","definition":"T1b (plaque +/- patch). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D505F8-B8B1-47BB-E053-F662850AA3BF","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86D505F8-B8CA-47BB-E053-F662850AA3BF","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","deletedIndicator":"No"},{"value":"T1a","valueDescription":"Mycosis Fungoides and Sezary Syndrome T1a TNM Finding v8","ValueMeaning":{"publicId":"6703329","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome T1a TNM Finding v8","longName":"6703329","preferredDefinition":"T1a (patch only). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome T1a TNM Finding v8","conceptCode":"C141332","definition":"T1a (patch only). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D505F8-B8D7-47BB-E053-F662850AA3BF","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86D505F8-B8F0-47BB-E053-F662850AA3BF","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","deletedIndicator":"No"},{"value":"T1","valueDescription":"Mycosis Fungoides and Sezary Syndrome T1 TNM Finding v8","ValueMeaning":{"publicId":"6703331","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome T1 TNM Finding v8","longName":"6703331","preferredDefinition":"Limited patches, papules, and/or plaques covering less than 10% of the skin surface. Note: for skin, patch indicates any size skin lesion without significant elevation or induration. Presence/absence of hypo- or hyperpigmentation, scale, crusting, and/or poikiloderma should be noted. Plaque indicates any size skin lesion that is elevated or indurated. Presence or absence of scale, crusting, and/or poikiloderma should be noted. Histologic features such as folliculotropism, large-cell transformation (more than 25% large cells), and CD30 positivity or negativity, as well as clinical features such as ulceration are important to document. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome T1 TNM Finding v8","conceptCode":"C141331","definition":"Limited patches, papules, and/or plaques covering less than 10% of the skin surface. Note: for skin, patch indicates any size skin lesion without significant elevation or induration. Presence/absence of hypo- or hyperpigmentation, scale, crusting, and/or poikiloderma should be noted. Plaque indicates any size skin lesion that is elevated or indurated. Presence or absence of scale, crusting, and/or poikiloderma should be noted. Histologic features such as folliculotropism, large-cell transformation (more than 25% large cells), and CD30 positivity or negativity, as well as clinical features such as ulceration are important to document. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D505F8-B8FD-47BB-E053-F662850AA3BF","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86D505F8-B916-47BB-E053-F662850AA3BF","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6703314","version":"1","preferredName":"Mycosis Fungoides and Sezary Syndrome Primary Tumor TNM Finding v8 American Joint Committee on Cancer T Category Category","preferredDefinition":"A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor (skin).:A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).:A grouping of items based on some commonality or by user defined characteristics.","longName":"C141330:C39315:C25728:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides and Sezary Syndrome Primary Tumor TNM Finding v8","conceptCode":"C141330","definition":"A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor (skin).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86D505F8-B7C6-47BB-E053-F662850AA3BF","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"ONEDATA","dateModified":"2019-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"86D505F8-B7D7-47BB-E053-F662850AA3BF","latestVersionIndicator":"Yes","beginDate":"2019-04-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-18","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeDescription":"4-18-19 created for standardization; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"6702791","version":"1","longName":"Mycosis Fungoides and Sezary Syndrome","context":"NCI Standards"}]}],"AlternateNames":[{"name":"CCR","type":"USED_BY","context":"CCR"}],"ReferenceDocuments":[{"name":"T category","type":"Preferred Question Text","description":"T category","url":null,"context":"NCI Standards"},{"name":"CCR Question Text","type":"Alternate Question Text","description":"Blood","url":null,"context":"CCR"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"86E28EAF-46F2-66CC-E053-F662850A19E4","latestVersionIndicator":"Yes","beginDate":"2019-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-19","modifiedBy":"COOPERM","dateModified":"2019-04-29","changeDescription":"4-19-19 created for standardization; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}